AllSci News
Bristol Myers Squibb pairs up with Faro on clinical protocol AI deployment
Faro, a San Diego-based digital protocol company, unveiled a multi-year collaboration with Bristol Myers Squibb to standardize on Faro’s digital protocol platform…
CSPC’s HER2 bispecific anbenitamab's Phase III challenges neoadjuvant breast cancer standard
CSPC Pharmaceutical Group (HKEX: 01093) announced on March 31 that anbenitamab (KN026), a HER2 bispecific antibody, met its pre-specified primary endpoint...
AstraZeneca's efzimfotase alfa posts mixed Phase III results for pediatric hypophosphatasia
Alexion, AstraZeneca's (LSE/STO/NYSE: AZN) rare disease unit, reported positive results from a three-trial Phase III programme for efzimfotase alfa in...
Takeda's zasocitinib aces Phase III in moderate-to-severe plaque psoriasis trials
Takeda (TSE:4502/NYSE:TAK) reported that zasocitinib, its investigational oral TYK2 inhibitor, met co-primary endpoints in two Phase III trials in adults...
BioVersys and Hackensack Meridian Health partner on novel ansamycin molecules for non-tuberculous mycobacteria
Novel ansamycin small molecules developed at Hackensack Meridian Health's Center for Discovery and Innovation are moving into joint profiling and...
Galapagos agrees with Gilead to take on Ouro Medicines' gamgertamig T cell engager
Gamgertamig, a BCMAxCD3 bispecific T cell engager developed by Ouro Medicines, sits at the center of a three-way collaboration agreement announced March 31...
Caribou’s off-the-shelf BCMA CAR-T receives RMAT designation for multiple myeloma
Caribou Biosciences, Inc. (Nasdaq: CRBU), headquartered in Berkeley, California, announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011,…
Tonix Pharma’s prophylactic mAb for Lyme disease demonstrates 4-month protection in Phase I
Tonix Pharmaceuticals (Nasdaq: TNXP) presented Phase I data for TNX-4800, a long-acting anti-OspA human monoclonal antibody being developed for Lyme disease prevention,…
Ambrosia Bio closes USD 100 million Series B to advance GLP-1 cardiometabolic pipeline
Boulder, Colorado-based Ambrosia Biosciences Inc. has closed an oversubscribed USD 100 million Series B financing round to advance its oral small molecule...
Biogen moves on Apellis Pharma for USD 5.6b to strengthen complement immunology portfolio
Biogen Acquires Apellis Pharmaceuticals to Consolidate Complement Immunology Portfolio in USD 5.6 Billion Deal
Eli Lilly expands from neuroscience to sleep medicine via USD 7.8b Centessa acquisition
Eli Lilly Expands Neuroscience Portfolio into Sleep Medicine via USD 7.8 Billion Acquisition of Centessa Pharmaceuticals
Lancet: Chia Tai's benmelstobart and anlotinib combo outperforms pembrolizumab in lung cancer trial
Researchers across 79 centres in China report that benmelstobart anlotinib lung cancer combination therapy produced statistically significant improvements...
BridgeBio's acoramidis shows sustained mortality reduction in 54-month ATTR-CM extension study
BridgeBio Pharma (Nasdaq: BBIO) reported 54-month open-label extension data for acoramidis (Attruby) in ATTR-CM showing a 44.7% reduction in all-cause...
Hengrui, Braveheart's cardiac myosin inhibitor shows stronng early efficacy against cardiomyopathy
Hengrui Pharma and Braveheart Bio reported Phase 2 results for HRS-1893 (BHB-1893), a selective small-molecule cardiac myosin inhibitor, in patients with...
Oncomatryx raises USD 67m to advance quantum ADC pipeline
San Sebastian, Spain-based Oncomatryx, a biotechnology company focused on tumor microenvironment-targeted therapies, has raised USD 67 million in a financing round to…
The AllSci Brief
Systematic R&D and deal news. Daily.